SCHEMBL778332

SCHEMBL778332

Clc1nc(Cl)nc(N2CCCCC2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
USP2 O75604 1/20 0.52
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
ATM Q13315 2/20 0.48
HTT P42858 1/20 0.48
RECQL P46063 1/20 0.48
HRH1 P35367 1/20 0.48
MAPK1 P28482 4/20 0.45
ALDH1A1 P00352 3/20 0.45
NPC1 O15118 1/20 0.45
GALR3 O60755 1/20 0.45
TP53 P04637 1/20 0.45
RAB9A P51151 1/20 0.45
CYP2C19 P33261 3/20 0.44
CYP2C9 P11712 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 1/20 0.44
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2242665 1.00 SMN1; SMN2 (0.52) SMN1; SMN2TDP1USP2MEN1KMT2A
SCHEMBL9336873 0.97 HRH1 (0.50) SMN1; SMN2TDP1USP2MEN1KMT2A
SCHEMBL1090112 0.95 SMN1; SMN2 (0.58) SMN1; SMN2TDP1USP2MEN1KMT2A
SCHEMBL8422457 0.95 SMN1; SMN2 (0.58) SMN1; SMN2TDP1USP2MEN1KMT2A
SCHEMBL28998684 0.95 SMN1; SMN2 (0.58) SMN1; SMN2TDP1USP2MEN1KMT2A
SCHEMBL9073359 0.92 HRH1 (0.56) SMN1; SMN2TDP1USP2MEN1KMT2A
SCHEMBL9418612 0.87 SORD (0.49) SMN1; SMN2TDP1USP2MEN1KMT2A
SCHEMBL1066847 0.85 ALDH1A1 (0.49) SMN1; SMN2TDP1USP2MEN1KMT2A
SCHEMBL19295119 0.85 MAPK1 (0.47) SMN1; SMN2TDP1USP2MEN1KMT2A
SCHEMBL778177 0.83 USP2 (0.81) SMN1; SMN2TDP1USP2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584757-B2 MK2 inhibitors and uses thereof CELGENE CAR LLC (BM) 2023-02-21 US disclosed
US-11584757-B2 MK2 inhibitors and uses thereof CELGENE CAR LLC (BM) 2023-02-21 US disclosed
EP-3912981-A1 MK2 INHIBITORS AND USES THEREOF CELGENE CAR LLC (BM) 2021-11-24 EP disclosed
EP-3912981-A1 MK2 INHIBITORS AND USES THEREOF CELGENE CAR LLC (BM) 2021-11-24 EP disclosed
EP-3193611-B1 MK2 INHIBITORS AND USES THEREOF CELGENE CAR LLC (BM) 2021-03-24 EP disclosed
EP-3193611-B1 MK2 INHIBITORS AND USES THEREOF CELGENE CAR LLC (BM) 2021-03-24 EP disclosed
US-20210053984-A1 MK2 INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2021-02-25 US disclosed
US-20210053984-A1 MK2 INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2021-02-25 US disclosed
CN-106998692-B MK2 inhibitors and uses thereof 西建卡尔有限责任公司 2020-09-08 CN disclosed
US-10577380-B2 MK2 inhibitors and uses thereof CELGENE CAR LLC (BM) 2020-03-03 US disclosed
EP-0326082-B1 FLAME-RETARDANT POLYPROPYLENE RESIN COMPOSITION Chisso Corporation (JP) 1993-09-22 EP disclosed
US-5158999-A Oligomers and-or polymers containing triazines and phosphine oxide units in the backbone MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-10-27 US disclosed
EP-0413613-A1 Flame retardants MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1991-02-20 EP disclosed
US-4966931-A POLYAMMONIUM PHOSPHATES, POLYTRIAZINES, POLYETHYLENE BLENDS CHISSO CORPORATION (JP) 1990-10-30 US disclosed
US-4939243-A Water-soluble copper complex disazo compounds containg a chloro triazinylamino group and a group of the vinylsulfone series as fiber-reactive groups and their dyestuffs HOECHST AKTIENGESELLSCHAFT (DE) 1990-07-03 US disclosed
EP-0326082-A2 Flame-retardant polypropylene resin composition Chisso Corporation (JP) 1989-08-02 EP disclosed
US-4675353-A PHOTOSTABILIZERS THE BFGOODRICH COMPANY (US) 1987-06-23 US disclosed
EP-0189877-A2 Hindered 2-keto-1,4-diazacycloalkane oligomers containing triazine rings or ester groups and compositions stabilized thereby The B.F. GOODRICH Company (US) 1986-08-06 EP disclosed
EP-0084849-B1 WATER SOLUBLE COPPER COMPLEXES OF DISAZO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS DYESTUFFS HOECHST AKTIENGESELLSCHAFT (DE) 1986-05-14 EP disclosed
EP-0084849-A2 Water soluble copper complexes of disazo compounds, process for their preparation and their use as dyestuffs HOECHST AKTIENGESELLSCHAFT (DE) 1983-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10577380-B2 MK2 inhibitors and uses thereof MKNK2, DUSP2, MKNK1 SMN1; SMN2 4098/4885TDP1 3334/4885USP2 874/4885
US-11584757-B2 MK2 inhibitors and uses thereof MKNK2, DUSP2, MKNK1 SMN1; SMN2 4098/4885TDP1 3334/4885USP2 874/4885
US-20210053984-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, DUSP2, MKNK1 SMN1; SMN2 4098/4885TDP1 3334/4885USP2 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.